12:00 AM
Mar 08, 2010
 |  BC Week In Review  |  Company News  |  Sales & Marketing

SpePharm, Paladin, TopoTarget sales and marketing update

SpePharm acquired all assets outside North and South America for TopoTarget's Savene dexrazoxane, which is marketed to treat anthracycline extravasations. TopoTarget will receive €5 million ($6.8 million) up front and is eligible for double-digit royalties capped...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >